In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Exelixis acquires X-Ceptor Therapeutics for cash and stock

Executive Summary

In a deal valued at about $24mm, genomics company Exelixis is acquiring all the outstanding stock (fully diluted) of privately held X-Ceptor Therapeutics (develops small-molecule modulators of nuclear hormone receptors--NHRs) for about $2.9mm in cash and 2.5mm of its common shares (valued at $8.43 apiece).
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Payment Includes Cash
    • Payment Includes Stock

Related Companies